Does the Rise of Specialty Pharmacogenomics Consultants Signal Stronger Market or Popularity? | GenomeWeb

If it takes a mature market to support a specialty consultant class, then the appearance of Genomic Healthcare Strategies, with its focus on pharmacogenomic-based medicine, could be a sign that the field is establishing itself.

Though it hasn’t yet made any money from clients, the new consulting company hopes to cater to individuals, companies, and “policy organizations” in molecular medicine, genomics, and therapeutics, by helping them “understand value and monetize opportunities,” said Kevin Batchelder, a consultant for the Charlestown, Mass.-based company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.